Natural AD-like neuropathology in octodon degus: Impaired burrowing and neuroinflammation

Current Alzheimer Research

Volumn 12, Issue 4, 2015, Pages 314-322

  Deacon, Robert M J ^a,e   Altimiras, Francisco J ^a   Bazán León, Enrique A ^b   Pyarasani, Rhada D ^c   Nachtigall, Fabiane M ^c   Santos, Leonardo S ^c   Tsolaki, Anthony G ^d   Pednekar, Lina ^d   Kishore, Uday ^d   Biekofsky, Rodolfo R ^e   Vásquez, Rodrigo A ^b   Cogram, Patricia ^a,e  

^a Fraunhofer Chile Research Foundation   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

^c UNIVERSIDAD DE TALCA   (Chile)

^d BRUNEL UNIVERSITY   (United Kingdom)

^e NEURO DVI LLP   (United Kingdom)

Author keywords

Alzheimer s disease; Beta amyloid; Burrowing; Complement; Cytokines; Octodon degus

Indexed keywords

ALPHA INTERFERON; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C9; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; RNA 18S; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DAILY LIFE ACTIVITY; FEMALE; GENE EXPRESSION; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; BRAIN; DISEASE MODEL; METABOLISM; MOTOR ACTIVITY; OCTODON; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; MALE; MOTOR ACTIVITY; OCTODON;

EID: 84929611667     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205012666150324181652     Document Type: Article

References (50)

1. Hampel H, Prvulovic D, Teipel S, Jessen F, Luckhaus C, Frolich L, et al. The future of Alzheimer's disease: the next 10 years. Prog Neurobiol 95: 718-728 (2011).
2. Wimo A, Jonsson L, Bond J, Prince M, Winblad B. The worldwide economic impact of dementia 2010. Alzheimers Dement 9: 1-11 (2013).
3. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet 377: 1019-1031 (2011).
4. Mayeux R, Stern Y. Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med 2: 1-18 (2012).
5. Braidy N, Muñoz P, Palacios AG, Castellano-Gonzalez G, Inestrosa NC, Chung RS, et al. Recent rodent models for Alzheimer's disease: clinical implications and basic research. J Neural Transm 119: 173-195 (2012).
6. Saraceno C, Musardo S, Marcello E, Pelucchi S, Di Luca M. Modeling Alzheimer's disease: from past to future. Front Pharmacol 4: 77 (2013).
7. Vásquez RA. Vigilance and social foraging in Octodon degus (Rodentia: Octodontidae) in central Chile. Revista Chilena de Historia Natural 70: 557-563 (1997).
8. Vásquez RA, Ebensperger LA, Bozinovic F. The influence of habitat on travel speed, intermittent locomotion, and vigilance in a diurnal rodent. Behav Ecology 13: 182-187 (2002).
9. Inestrosa NC, Reyes AE, Chacón MA, Cerpa W, Villalón A, Montiel J, et al. Human-like rodent amyloid-H-peptide determines Alzheimer pathology in aged wild-type Octodon degus. Neurobiol Aging 26: 1023-1028 (2005).
10. Ardiles AO, Tapia-Rojas CC, Mandal M, Alexandre F, Kirkwood A, Inestrosa NC, et al. Postsynaptic dysfunction is associated with spatial and object recognition memory loss in a natural model of Alzheimer's disease. Proc Natl Acad Sci USA 109: 13835-13840 (2012).
11. Tarragon E, Lopez D, Estrada C, Ana GC, Schenker E, Pifferi F, et al. Octodon degus: a model for the cognitive impairment associated with Alzheimer's disease. CNS Neurosci Ther 19: 643-648 (2013).
12. Castro-Fuentes R, Socas-Pérez R. Octodon degus: A Strong Attractor for Alzheimer Research. Basic Clin Neurosci 4: 91-96 (2013).
13. Deacon RMJ, Raley JM, Perry VH, Rawlins JNP. Burrowing into prion disease. Neuroreport 12: 2053-2057 (2001).
14. Contet C, Rawlins JNP, Deacon RMJ. A comparison of 129S2/SvHsd and C57BL/6JOlaHsd mice on a test battery assessing sensorimotor, affective and cognitive behaviors: implications for the study of genetically modified mice. Behav Brain Res 124: 33-46 (2001).
15. Guenther K, Deacon RMJ, Perry VH, Rawlins JNP. Early behavioral changes in scrapie-affected mice and the influence of dapsone. Eur J Neurosci 14: 401-409 (2001).
16. Deacon RMJ, Bannerman DM, Kirby BP, Croucher A, Rawlins JNP. Effects of cytotoxic hippocampal lesions in mice on a cognitive test battery. Behav Brain Res 133: 57-68 (2002).
17. Cunningham C, Deacon RMJ, Wells H, Boche D, Waters S, PicancoDiniz C, et al. Synaptic changes characterize early behavioral signs in the ME7 model of murine prion disease. Eur J Neurosci 17: 2147-2155 (2003).
18. Deacon RMJ, Rawlins JNP. Hippocampal lesions, species-typical behaviors and anxiety in mice. Behav Brain Res 156: 241-249 (2005).
19. Deacon RMJ. Burrowing in rodents: a sensitive method for detecting behavioral dysfunction. Nat Protocols 1: 118-121 (2006).
20. Deacon RMJ. Burrowing: A sensitive behavioral assay, tested in five species of laboratory rodents. Behav Brain Res 200: 128-133 (2009).
21. Deacon RMJ. Digging in Mice: Marble Burying, Burrowing, and Direct Observation Reveal Changes in Mouse Behavior. In (ed. Gould TD) Mood and anxiety related phenotypes in mice. From: Neuromethods 42. New York: Humana Press, pp. 37- 45 (2009).
22. Deacon RMJ. A Novel Approach to Discovering Treatments for Alzheimer's Disease. J Alzheimer's Dis Parkinsonism 4: 142 (2014).
23. Bonifati DM, Kishore U. Role of complement in neurodegeneration and neuroinflammation. Mol Immunol 44: 999-1010 (2007).
24. Krstic D, Madhusudan A, Doehner J, Vogel P, Notter T, Imhof C, et al. Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. J Neuroinflammation 9: 151-173 (2012).
25. Shastri A, Bonifati DM, Kishore U. Innate Immunity and Neuroinflammation. Mediators Inflamm 2013: 342931(2013).
26. Krstic D, Knuesel I. Deciphering the mechanism underlying lateonset Alzheimer disease. Nat Rev Neurol 9: 25-34 (2013).
27. Kenagy GJ, Nespolo RF, Vásquez RA, Bozinovic F. Daily and seasonal limits of time and temperature to activity of degus. Revista Chilena de Historia Natural 75: 567-581 (2002).
28. Vásquez RA, Grossi B, Márquez IN. On the value of information: studying changes in patch assessment abilities through learning. Oikos 112: 298-310 (2006).
29. Small SA, Schobel SA, Buxton RB, Witter MP, Barnes CA. A pathophysiological framework of hippocampal dysfunction in ageing and disease. Nat Rev Neurosci 12: 585-601 (2011).
30. van Groen T, Kadish I, Popovic N, Popovic M, Caballero-Bleda M, Baño-Otálora B, et al. Age-related brain pathology in Octodon degus: Blood vessel, white matter and Alzheimer-like pathology. Neurobiol Aging 32: 1651-1661 (2011).
31. Potkin SG. The ABC of Alzheimer's disease: ADL and improving day-to-day functioning of patients. Int Psychogeriatr 14: 7-26 (2002).
32. Reisberg B, Finkel S, Overall J, Schmidt-Gollas N, Kanowski S, Lehfeld H, et al. The Alzheimer's disease activities of daily living international scale (ADL-IS). Int Psychogeriatr 13: 163-181 (2001).
33. De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV. Alzheimer's disease. Subcell Biochem 65: 329-52 (2012).
34. Zhang YW, Thompson R, Zhang H, Xu H. APP processing in Alzheimer's disease. Mol Brain 4: 3 (2011).
35. Gelfanova V, Higgs RE, Dean RA, Holtzman DM, Farlow MR, Siemers ER, et al. Quantitative analysis of amyloid-β peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry. Brief Funct Genomic Proteomic 6: 149-58 (2007).
36. Deacon RM, Glass L, Snape M, Hurley MJ, Altimiras FJ, Biekofsky RR, et al. NNZ-2566, a novel analog of (1-3)IGF-1, as a potential therapeutic agent for fragile X syndrome. Neuromolecular Med 17: 71-82 (2015).
37. Amara FM, Junaid A, Clough RR, Liang B. TGF-β(1), regulation of Alzheimer amyloid precursor protein mRNA expression in a normal human astrocyte cell line: mRNA stabilization. Mol Brain Res 71: 42-49 (1999).
38. Matsui T, Ingelsson M, Fukumoto H, Ramasamy K, Kowa H, Frosch MP, et al. Expression of APP pathway mRNAs and proteins in Alzheimer's disease. Brain research 1161: 116-123 (2007).
39. Forloni G, Demicheli F, Giorgi S, Bendotti C, Angeretti N. Expression of amyloid precursor protein mRNAs in endothelial, neuronal and glial cells: modulation by interleukin-1. Mol Brain Res 16: 128-134 (1992).
40. Couttas TA, Kain N, Daniels B, Lim XY, Shepherd C, Kril J, et al. Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer's disease pathogenesis. Acta Neuropathol Commun 2: 9 (2014).
41. Liu CC, Kanekiyo T, XuH, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms, and therapy. Nat Rev Neurol 9: 106-118 (2013).
42. Jhang KA, Lee EO, Kim HS, Chong YH. Norepinephrine provides short-term neuroprotection against Aβ1-42 by reducing oxidative stress independent of Nrf2 activation. Neurobiol Aging 35: 2465- 2473 (2014).
43. El Khoury J, Luster AD. Mechanism of microglia accumulation in Alzheimer's disease: therapeutic implications. Trends Pharmacol Sci 29: 626-632 (2008).
44. Walker DG, Kim SU, McGeer PL. Complement and cytokine gene expression in cultured microglial derived from postmortem human brains. J Neurosci Res 40: 478-493 (1995).
45. Wyss-Coray T, Muckle I. Inflammation in neurodegenerative disease: a double-edged sword. Neuron 35: 419-432 (2002).
46. Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, et al. Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci USA 89: 10016-10020 (1992).
47. Lue LF, Rydel R, Brigham EF, Yang LB, Hampel H, Murphy GM Jr, et al. Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia 35: 72-79 (2001).
48. Kishore U, Gupta SK, Perdikoulis MV, Kojouharova MS, Urban BC, Reid KB. Modular organization of the carboxy-terminal, globular head region of human C1q A, B and C chains. J Immunol 17: 812-820 (2003).
49. Fonseca MI, Kawas CH, Troncoso JC, Tenner AJ. Neuronal localization of C1q in preclinical Alzheimer's disease. Neurobiol Dis 15: 40-46 (2004).
50. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci USA 101: 2173-2178 (2004).